Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eli Lilly
Biotech
Lilly changes lead psoriasis program from $2.4B Dice buyout
Lilly kicked DC-806 to the curb as part of a third-quarter cull that also affected the PD-1 autoimmune prospect peresolimab.
Nick Paul Taylor
Oct 30, 2024 10:00am
Alzheimer's trials withheld brain injury risk disclosures: NYT
Oct 24, 2024 11:33am
Eli Lilly unveils 2 new research centers in China
Oct 15, 2024 5:30pm
Lilly picks UK for 1st Gateway Lab in Europe
Oct 14, 2024 10:35am
Lilly goes all-in on AI with new exec position—Chutes & Ladders
Oct 11, 2024 8:30am
AI-powered Insitro taps Lilly to clear path to clinic for siRNA
Oct 9, 2024 9:28am
